Answer
The selected product is licensed for pulmonary arterial hypertension in children aged 6 to under 18 years when used with an endothelin receptor antagonist. It is not licensed for paediatric chronic thromboembolic pulmonary hypertension.
Sources for this answer
- Adempas 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg, 2.5 mg film-coated tabletsemc · SmPC Current selected SmPC · Version 16